CA2353798A1 - Formule a liberation prolongee comprenant la gonadoliberine-ii - Google Patents

Formule a liberation prolongee comprenant la gonadoliberine-ii Download PDF

Info

Publication number
CA2353798A1
CA2353798A1 CA002353798A CA2353798A CA2353798A1 CA 2353798 A1 CA2353798 A1 CA 2353798A1 CA 002353798 A CA002353798 A CA 002353798A CA 2353798 A CA2353798 A CA 2353798A CA 2353798 A1 CA2353798 A1 CA 2353798A1
Authority
CA
Canada
Prior art keywords
polymer
osteoporosis
peptide
disorder
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002353798A
Other languages
English (en)
Inventor
Steve Qi
Karen Akinsanya
Amanda Hayward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring BV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2353798A1 publication Critical patent/CA2353798A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/23—Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette formule pharmaceutique est destinée à la libération prolongée d'un peptide thérapeutique, ou d'un sel de celui-ci, lequel peptide possède la séquence pyroGlu-His-Trp-Ser-Xaa?1¿Gly-Xaa?2¿-Xaa?3¿-Pro-Gly-NH¿2? Dans laquelle Xaa?1¿ représente His ou Tyr, Xaa?2¿ représente Trp ou Leu, et Xaa?3¿ représente Tyr ou Arg, à condition que lorsque Xaa?1¿ représente Tyr et Xaa?2¿ représente Leu, alors Xaa?3¿ ne représente pas Arg, et elle comprend en outre un polymère biodégradable, acceptable sur le plan pharmacologique. On peut utiliser cette formule pour traiter des troubles des os et de la prostate.
CA002353798A 1998-12-03 1999-12-02 Formule a liberation prolongee comprenant la gonadoliberine-ii Abandoned CA2353798A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9826662A GB2344287A (en) 1998-12-03 1998-12-03 Controlled release pharmaceutical formulation
GB9826662.0 1998-12-03
PCT/GB1999/004045 WO2000032218A1 (fr) 1998-12-03 1999-12-02 Formule a liberation prolongee comprenant la gonadoliberine-ii

Publications (1)

Publication Number Publication Date
CA2353798A1 true CA2353798A1 (fr) 2000-06-08

Family

ID=10843631

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002353798A Abandoned CA2353798A1 (fr) 1998-12-03 1999-12-02 Formule a liberation prolongee comprenant la gonadoliberine-ii

Country Status (22)

Country Link
EP (1) EP1140133A1 (fr)
JP (1) JP2002531411A (fr)
KR (1) KR20010089538A (fr)
CN (1) CN1332635A (fr)
AU (1) AU770676B2 (fr)
BR (1) BR9915943A (fr)
CA (1) CA2353798A1 (fr)
CZ (1) CZ20011893A3 (fr)
EE (1) EE200100293A (fr)
GB (1) GB2344287A (fr)
HR (1) HRP20010421A2 (fr)
HU (1) HUP0104943A3 (fr)
IL (1) IL143496A0 (fr)
MX (1) MXPA01005543A (fr)
NO (1) NO20012636L (fr)
NZ (1) NZ511984A (fr)
PL (1) PL348575A1 (fr)
RU (1) RU2233170C2 (fr)
SK (1) SK7552001A3 (fr)
TR (1) TR200102273T2 (fr)
WO (1) WO2000032218A1 (fr)
ZA (1) ZA200104530B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007012430A1 (fr) * 2005-07-26 2007-02-01 Georg-August-Universität-Göttingen Methode pouvant induire et accelerer l'apoptose dans des cellules cancereuses
GB0616111D0 (en) 2006-06-16 2006-09-20 Ardana Bioscience Ltd Agents, methods and uses
CN102448482A (zh) 2009-03-27 2012-05-09 范安德尔研究所 甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法
WO2011032099A1 (fr) 2009-09-11 2011-03-17 The Board Of Trustees Of The University Of Illinois Méthodes pour traiter un disfonctionnement diastolique et états associés
US20120208762A1 (en) 2009-10-27 2012-08-16 The Board Of Trustees Of The University Of Illinois Methods of Diagnosing Diastolic Dysfunction
WO2011075393A2 (fr) 2009-12-18 2011-06-23 Indiana University Research And Technology Corporation Co-agonistes du récepteur du glucagon/glp-i
KR20120123443A (ko) 2010-01-27 2012-11-08 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 대사 장애 및 비만 치료용 글루카곤 길항제-ｇｉｐ 항진제 콘쥬게이트
ES2575160T3 (es) 2010-03-15 2016-06-24 The Board Of Trustees Of The University Of Illinois Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
EP2582719B1 (fr) 2010-06-16 2016-08-10 Indiana University Research and Technology Corporation Agonistes de l'insuline à une seule chaîne très actifs au niveau du récepteur à l'insuline
US20120004182A1 (en) 2010-07-02 2012-01-05 Carsten Gruendker Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells
US9029502B2 (en) 2010-12-20 2015-05-12 The Regents Of The University Of Michigan Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
MA34885B1 (fr) 2010-12-22 2014-02-01 Indiana Unversity Res And Technology Corp Analogues du glucagon presentant una ctivite de recepteur de gip
LT2723367T (lt) 2011-06-22 2017-08-25 Indiana University Research And Technology Corporation Bendri gliukagono/glp-1 receptoriaus agonistai
US9415123B2 (en) 2011-10-10 2016-08-16 The Regents Of The University Of Michigan Polymeric nanoparticles for ultrasound imaging and therapy
BR112014007124A2 (pt) 2011-11-17 2017-06-13 Univ Indiana Res & Tech Corp superfamília de peptídeos gluxagon que exibem atividade no receptor glicocorticóide
JP6392123B2 (ja) 2011-12-20 2018-09-19 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 糖尿病治療のためのｃｔｐ系インスリンアナローグ
KR20150023729A (ko) 2012-06-14 2015-03-05 암브룩스, 인코포레이티드 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체
BR112014031671A2 (pt) 2012-06-21 2018-08-07 Hoffmann La Roche análogos de glucagon exibindo atividade de receptor gip
AR091477A1 (es) 2012-06-21 2015-02-04 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
JP6387008B2 (ja) 2012-09-26 2018-09-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリンアナローグダイマー
JP6538645B2 (ja) 2013-03-14 2019-07-03 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ インスリン‐インクレチン複合物
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
CN108271356A (zh) 2014-09-24 2018-07-10 印第安纳大学研究及科技有限公司 肠降血糖素-胰岛素缀合物
EP3250609A4 (fr) 2015-01-26 2018-07-11 The University of Chicago Agents de liaison à l'il13ra alpha 2 et leur utilisation dans le traitement du cancer
EP3250611B1 (fr) 2015-01-26 2021-04-21 The University of Chicago Lymphocytes t à récepteur d'antigène chimérique (car) reconnaissant le récepteur il 13r-alpha2 spécifique au cancer
CN104789524A (zh) * 2015-04-30 2015-07-22 四川大学 骨质疏松大鼠原代成骨细胞分离培养方法及应用
US20180201937A1 (en) 2015-08-04 2018-07-19 The University Of Chicago Inhibitors of cacna1a/alpha1a subunit internal ribosomal entry site (ires) and methods of treating spinocerebellar ataxia type 6
WO2018134370A1 (fr) * 2017-01-20 2018-07-26 Immune System Regulation Holding Ab Nouveaux composés (immunorhélines)
CN110996953A (zh) 2017-06-30 2020-04-10 安进公司 用心脏肌小节激活剂治疗心力衰竭的方法
BR122021015266B1 (pt) 2017-08-03 2023-01-24 Amgen Inc. Conjugado compreendendo muteína de il-21 e anticorpo anti-pd, kit e composição farmacêutica
ES2928576T3 (es) 2017-09-08 2022-11-21 Amgen Inc Inhibidores de KRAS G12C y métodos de uso de los mismos
SG11202002114RA (en) 2017-09-18 2020-04-29 Univ California Claudin6 antibodies and methods of treating cancer
JP2019122373A (ja) 2018-01-12 2019-07-25 アムジエン・インコーポレーテツド 抗ｐｄ−１抗体及び治療方法
WO2020055913A1 (fr) 2018-09-10 2020-03-19 Cardax, Inc. Procédés de réduction de la protéine c réactive et/ou de traitement d'une maladie cardiovasculaire
KR20210154158A (ko) 2019-03-20 2021-12-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 클라우딘-6 항체 및 약물 컨쥬게이트
WO2020191344A1 (fr) 2019-03-20 2020-09-24 The Regents Of The University Of California Anticorps de claudin-6 bispécifiques
EP3785734B1 (fr) * 2019-03-26 2023-04-12 Novel Pharma Inc. Dérivé de gnrh de liaison aux acides gras à action prolongée et composition pharmaceutique contenant celui-ci
WO2020210376A1 (fr) 2019-04-09 2020-10-15 The Board Of Trustees Of The University Of Illinois Charbon actif hautement poreux à adsorption de médicament pour une administration de médicament améliorée
US20230190725A1 (en) 2019-04-29 2023-06-22 The Board Of Trustees Of The University Of Illinois Mek inhibitors for corneal scarring and neovascularization
WO2020222668A1 (fr) 2019-04-30 2020-11-05 Instituto de Medicina Molecular João Lobo Antunes Inhibiteurs de la voie rank en combinaison avec des inhibiteurs de cdk
WO2020263793A1 (fr) 2019-06-24 2020-12-30 Amgen Inc. Inhibition de la sirp-gamma pour le traitement du cancer
US20220280561A1 (en) 2019-08-30 2022-09-08 Research Institute At Nationwide Children's Hospital Copper-atsm for treating neurodegenerative disorders associted with mitochondrial dysfunction
TW202216778A (zh) 2020-07-15 2022-05-01 美商安進公司 Ｔｉｇｉｔ及ｃｄ１１２ｒ阻斷
CA3208974A1 (fr) 2021-01-20 2022-07-28 Bioentre Llc Proteines de liaison a ctla4 et methodes de traitement du cancer
WO2023137161A1 (fr) 2022-01-14 2023-07-20 Amgen Inc. Triple blocage de tigit, cd112r et pd-l1
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH661206A5 (fr) * 1983-09-23 1987-07-15 Debiopharm Sa Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
DE3414595A1 (de) * 1984-04-18 1985-10-31 Hoechst Ag, 6230 Frankfurt Verwendung von gonadoliberin und gonadoliberinagonisten zur behandlung klimakterischer beschwerden
US4540513A (en) * 1984-09-25 1985-09-10 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Decapeptide having gonadotropin releasing activity
US4721775A (en) * 1985-08-26 1988-01-26 Board Of Regents, The University Of Texas System Effective peptides related to the luteinizing hormone releasing hormone from L-amino acids
NZ240214A (en) * 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
CA2192773C (fr) * 1995-12-15 2008-09-23 Hiroaki Okada Obtention d'une preparation a liberation prolongee pour injection
WO1997047743A1 (fr) * 1996-06-13 1997-12-18 Zymogenetics, Inc. Recepteur humain de l'hormone de liberation de la gonadotrophine de type ii

Also Published As

Publication number Publication date
PL348575A1 (en) 2002-06-03
CN1332635A (zh) 2002-01-23
MXPA01005543A (es) 2003-07-14
ZA200104530B (en) 2002-06-04
WO2000032218A1 (fr) 2000-06-08
IL143496A0 (en) 2002-04-21
EP1140133A1 (fr) 2001-10-10
NO20012636L (no) 2001-07-12
HRP20010421A2 (en) 2002-06-30
BR9915943A (pt) 2001-08-21
JP2002531411A (ja) 2002-09-24
HUP0104943A2 (en) 2002-06-29
EE200100293A (et) 2002-08-15
NZ511984A (en) 2002-11-26
GB2344287A (en) 2000-06-07
AU1573200A (en) 2000-06-19
SK7552001A3 (en) 2002-02-05
GB9826662D0 (en) 1999-01-27
CZ20011893A3 (cs) 2002-05-15
NO20012636D0 (no) 2001-05-29
RU2233170C2 (ru) 2004-07-27
HUP0104943A3 (en) 2002-08-28
TR200102273T2 (tr) 2001-12-21
AU770676B2 (en) 2004-02-26
KR20010089538A (ko) 2001-10-06

Similar Documents

Publication Publication Date Title
AU770676B2 (en) Controlled release formulation comprising GnRH-II
KR930008095B1 (ko) Lhrh 길항제로서 유용한 lhrh의 노나펩타이드 및 데카펩타이드 동족체
AU709197B2 (en) Peptide compositions with growth factor-like activity
US5084555A (en) An octapeptide bombesin analog
US5244883A (en) Nonapeptide bombesin antagonists
CA2269655C (fr) Compositions de peptides dotees d'une activite ressemblant a celle des facteurs de croissance
EP0646127B1 (fr) Polypeptides antagonistes de la bombesine
WO1994021674A9 (fr) Polypeptides antagonistes de la bombesine
WO1991004040A1 (fr) Traitement de cancer du colon
EP1124847B1 (fr) Analogues de lh-rh pour le traitement de l'osteoporose
HRP20020810A2 (en) Novel lhrh-antagonists, production and use thereof as medicament
EP0737691A1 (fr) Analogues de bombésine
US5439884A (en) Method of controlling fertilization using bombesin or its agonist

Legal Events

Date Code Title Description
FZDE Discontinued